Age

22–any

Sex

ALL

Healthy volunteers

Not accepted

Clinician-confirmed diagnosis of Major Depressive Disorder
Currently being treated with an antidepressant medication
Currently receiving or initiating TMS or esketamine at YNHH IPS
For those receiving TMS, they must be able to initiate Rejoyn within the first two weeks of beginning TMS
Experiencing at least mild depressive symptoms as defined by QIDS of ≥6
Clinician determines patient is appropriate for Rejoyn and prescribes it as part of standard care
Able to access and use a compatible smartphone
Able to provide informed consent for use of clinical data in research

Clinician determines Rejoyn is not suitable or safe for the patient
Significant cognitive impairment that prevents app use
Insufficient English proficiency to use Rejoyn
Concurrent participation in another interventional study that would interfere with naturalistic data

REWIRE: Real-world Engagement With Interventional and Rejoyn Effectiveness